Second cancer risk in childhood cancer survivors treated with intensity-modulated radiation therapy (IMRT)

2014 ◽  
Vol 62 (2) ◽  
pp. 311-316 ◽  
Author(s):  
Dana L. Casey ◽  
Danielle N. Friedman ◽  
Chaya S. Moskowitz ◽  
Patrick D. Hilden ◽  
Charles A. Sklar ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Cancer Risk ◽  
Cancer Survivors ◽  
Childhood Cancer ◽  
Intensity Modulated Radiation Therapy ◽  
Childhood Cancer Survivors ◽  
Second Cancer ◽  
Intensity Modulated ◽  
Second Cancer Risk

Meta-analysis of second cancer risk after radiotherapy among childhood cancer survivors

2011 ◽  
Vol 146 (1-3) ◽  
pp. 263-267 ◽  
Author(s):  
K. Doi ◽  
M. N. Mieno ◽  
Y. Shimada ◽  
H. Yonehara ◽  
S. Yoshinaga
Keyword(s):  
Cancer Risk ◽  
Cancer Survivors ◽  
Childhood Cancer ◽  
Meta Analysis ◽  
Childhood Cancer Survivors ◽  
Second Cancer ◽  
Second Cancer Risk

Intensity Modulated Radiation Therapy and Second Cancer Risk in Adults

2018 ◽  
Vol 100 (1) ◽  
pp. 17-20 ◽  
Author(s):  
Andrea Riccardo Filippi ◽  
Valentina Vanoni ◽  
Bruno Meduri ◽  
Luca Cozzi ◽  
Marta Scorsetti ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Cancer Risk ◽  
Intensity Modulated Radiation Therapy ◽  
Second Cancer ◽  
Intensity Modulated ◽  
Second Cancer Risk

scholarly journals Second Cancer Risk in Childhood Cancer Survivors Treated With Intensity-Modulated Radiation Therapy (IMRT): An Updated Analysis of More Than 10 Years of Follow-Up

2021 ◽  
Author(s):  
Kathryn Tringale ◽  
Dana Casey ◽  
Gregory Niyazov ◽  
Jessica Lavery ◽  
Chaya Moskowitz ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Cancer Survivors ◽  
Childhood Cancer ◽  
Radiation Treatment ◽  
Intensity Modulated Radiation Therapy ◽  
Childhood Cancer Survivors ◽  
Malignant Neoplasms ◽  
High Dose ◽  
Intensity Modulated ◽  
Second Malignant Neoplasms

Background It is unclear how intensity-modulated radiation therapy (IMRT) impacts long-term risk of second malignant neoplasms (SMNs) in childhood cancer patients. Procedure Patients aged 10 years, many solid SMNs after IMRT in childhood cancer survivors develop in the high dose region. These data serve as a foundation for comparison with other modalities of radiation treatment (e.g., proton therapy).

scholarly journals Comparing second cancer risk for multiple radiotherapy modalities in survivors of hodgkin lymphoma

2020 ◽  
pp. 20200354
Author(s):  
Claire Timlin ◽  
James Loken ◽  
Jon Kruse ◽  
Robert Miller ◽  
Uwe Schneider
Keyword(s):  
Radiation Therapy ◽  
Cancer Risk ◽  
Hodgkin Lymphoma ◽  
Treatment Modalities ◽  
Solid Cancer ◽  
Average Risk ◽  
Second Cancer ◽  
Parameter Uncertainties ◽  
Intensity Modulated ◽  
Second Cancer Risk

Objectives: To assess if Excess Absolute Risk (EAR) of radiation-induced solid cancer can be used to rank radiotherapy plans for treatment of Hodgkin Lymphoma (HL) in a statistically significant way. Methods: EAR models, calibrated with data from the Life Span Study and HL survivors, have been incorporated into a voxelised risk-calculation software, which is used to compare four treatment modalities planned for five virtual HL patients. Organ-specific parameters are generated repeatedly in a Monte Carlo fashion to model their uncertainties. This in turn enables a quantitative estimation of the EAR uncertainties. Results: Parameter driven uncertainties on total EAR are around 13%, decreasing to around 2–5% for relative EAR comparisons. Total EAR estimations indicate that Intensity Modulated Proton Therapy decreases the average risk by 40% compared to the Intensity Modulated Radiation Therapy plan, 28% compared to the Volumetric Modulated Arc Therapy plan whereas the 3D Conformal Radiation Therapy plan is equivalent within the uncertainty. Conclusions: Relative EAR is a useful metric for distinguishing between radiotherapy plans in terms of second cancer risk. Advances in knowledge: Relative EAR is not dominated by model or parameter uncertainties and can be used to guide the choice of radiotherapy for HL patients.

scholarly journals The Rising Incidence of Second Cancers: Patterns of Occurrence and Identification of Risk Factors for Children and Adults

2014 ◽  
pp. e57-e67 ◽  
Author(s):  
Lindsay M. Morton ◽  
Kenan Onel ◽  
Rochelle E. Curtis ◽  
Eric A. Hungate ◽  
Gregory T. Armstrong
Keyword(s):  
Risk Factors ◽  
Cancer Risk ◽  
Cancer Survivors ◽  
Childhood Cancer ◽  
Genetic Susceptibility ◽  
Genome Wide Association Study ◽  
Second Cancer ◽  
Second Cancers ◽  
A Genome ◽  
Second Cancer Risk

As the population of cancer survivors has increased and continues to age, the occurrence of second cancers has risen dramatically—from 9% of all cancer diagnoses in 1975–1979 to 19% in 2005–2009. The Childhood Cancer Survivor Study, a cohort of more than 14,000 childhood cancer survivors with detailed exposure data and long-term follow-up, has substantially contributed to our understanding of the roles of radiotherapy and chemotherapy in second cancer occurrence. In particular, dose-related risks have been demonstrated for second cancers of the breast, thyroid, central nervous system, gastrointestinal tract, and sarcomas following radiation. Cytotoxic chemotherapy—which has long been known to be leukemogenic—also appears to contribute to risk for a range of other second cancer types. Individuals who develop a second cancer are at particularly high risk for developing additional second cancers. A genome-wide association study of survivors of Hodgkin lymphoma who received radiotherapy identified a locus on chromosome 6q21 as being associated with second cancer risk, demonstrating that recent advances in genomics are likely to prove invaluable for elucidating the contribution of genetic susceptibility to second cancer etiology. Among adults, risk of second cancers varies substantially by type of first and second cancer, patient age, and prevalence of second cancer risk factors, including primary cancer treatments, environmental and lifestyle exposures, and genetic susceptibility. Further research is needed to quantify second cancer risks associated with specific etiologic factors and to identify the patients at highest risk of developing a second cancer to target prevention and screening efforts.

Sign in / Sign up

Export Citation Format

Share Document